Overview

Baricitinib Plus Glucocorticoid for Eosinophilia in IgG4-RD

Status:
Recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
Evaluation of efficacy and safety of Baricitinib combined with glucocorticoid in patients of IgG4-related disease with eosinophilia.
Phase:
N/A
Details
Lead Sponsor:
Wen Zhang
Collaborators:
Beijing Friendship Hospital
Tongji Hospital
Treatments:
Prednisolone